Androgen and androgen receptors (AR) play critical roles in the proliferation of prostate cancer through transcriptional regulation of target genes. Here, we found that androgens upregulated the expression of dynamin-related protein 1 (Drp1), which is involved in the induction of protein that promotes mitochondrial fusion, a process which opposes fission. We suggest that androgen-increased Drp1 enhanced MF leading to apoptosis. The present study demonstrates a novel role for androgens in the regulation of mitochondrial morphology that could potentially be utilized in prostate cancer therapy.
Introduction
Prostate cancer is a major cause of death among men in western countries. Androgens, through its binding to the androgen receptor (AR), induce the proliferation of prostate cells and are responsible for the progression of the cancer (1, 2) . Androgen ablation is the most commonly used therapy for prostate cancer. However, androgen ablation often leads to progression of the tumor towards androgen-depletion independent (ADI) status, which is more difficult to treat (3, 4) . In most ADI prostate cancers, the AR is over-expressed and aberrantly activated despite the elimination of androgens (5) .
Mitochondria have gained much attention for its paradoxical roles in cell survival and cell death (6) . Mitochondrial morphology can be rapidly altered by mitochondrial fission and fusion in response to the physiological requirements of a cell (7) . Mitochondrial fission requires translocation of the cytoplasmic dynamin-related protein 1 (Drp1) to the mitochondria where it interacts with the outer mitochondrial membrane protein, Fission 1 or Fis1 (8) (9) (10) (11) . Drp1 via its GTPase activity performs the scission of the outer mitochondrial membrane (12, 13) . Functional impairment of Drp1 results in aggregates of large, interconnected mitochondria characteristic of unfragmented mitochondria (14) . Post-translational modifications of Drp1 such as phosphorylation (14) (15) (16) , ubiquitination (17) , sumoylation (18, 19) , and S-nitrosylation (20) affect the function of Drp1. During mitosis, Cdk1/cyclin B mediates Drp1 phosphorylation at Ser-616 (16, 21) to promote mitochondrial fission. On the contrary, cyclic AMP-dependent phosphorylation of Drp1 at Ser-637 reduced mitochondrial fission (14, 15, 22) . Thus, Drp1 function seems to be affected by the site of phosphorylation. In contrast to Drp1 function, mitofusin proteins 1 and 2 (Mfn1 and Mfn2, respectively) are essential for GTP-dependent mitochondrial fusion (7) . Balance between mitochondrial fission and fusion events are necessary for normal functioning of the cell (23) . Although mitochondrial fission (fragmentation) is part of both mitosis and apoptosis, it is not clear why fission leads in one case to cell division (16) and in another to cell death (24) (25) (26) . Therefore, a better understanding of the regulation of proteins involved in mitochondrial fission and fusion is critical.
The objective of this research was to examine the regulation of Drp1 and its role in mitochondrial fission in prostate cancer cells. Results presented here demonstrate that androgen regulated Drp1 expression at the transcriptional level. Androgen-induced expression of Drp1 and its phosphorylation at Ser-616 correlated with androgen-induced cell proliferation.
However, when the cells were treated with CGP37157 (CGP), which is known to affect mitochondrial function by inhibiting a mitochondrial sodium-calcium exchanger to induce mitochondrial calcium overload, androgen-induced Drp1 facilitated a significant increase in mitochondrial fission and apoptosis. Thus, we demonstrate that androgens function as a proapoptotic agent when mitochondrial function is disrupted. These results provide a novel alternative to induce apoptosis in prostate cancer cells by taking advantage of AR activationinduced Drp1 expression to sensitize prostate cancer cells to drugs that compromise mitochondrial function.
Materials and Methods

Reagents
The following mammalian expression plasmids were used: pAcGFP1-Mito (mito-green), a green fluorescent label for mitochondria (Clonetech Laboratories, Inc. Mountain View, CA); dominant-negative Drp1 (DN-Drp1, K38A) (a kind gift from Alexander van der Bliek, University of California, Los Angeles, CA). Antibodies used were: anti-Drp1 (BD Biosciences, San Jose, CA); anti-PSA and anti-AR (Santa Cruz Biotechnology Inc., Santa Cruz, CA); anti-Mfn1 (Novus Biologicals Littleton, CO); anti-phospho-Drp1 (Ser-616), anti-COXIV, anti-mouse and anti-rabbit electroporation using the Electro Square Porator TM ECM-830 (BTX Inc, San Diego, CA), followed by G418 (500μg/ml) selection.
Protein Extraction and Western Blotting
Cell lysates were processed as described previously (27) . For phosphorylation studies, phosphatase inhibitor cocktail 1 and 2 were added (Sigma-Aldrich Corporation, St. Louis, MO)
to the lysis buffer.
Quantitative Real-Time Reverse Transcription-PCR
Total RNA was extracted using TRIzol (InVitrogen, Carlsbad, CA). The cDNA was synthesized using a Reverse Transcription System (Promega Corporation, Madison, WI) and was amplified by qRT-PCR using Mastercycler ep-realplex 2 (Eppendorf, Westbury, NY) with the IQ TM SYBR®
Green Supermix (Bio-Rad Laboratories, Hercules, CA). Primers used in this study were: Drp1:
5´-CCAAGGTGCCTGTAGGTGAT-3´ and 5´-CAGCAGTGACAGCGAGGATA-3´; PSA: 5´-CATCAGGAACAAAAGCGTGA-3´and 5´-AGCTGTGGCTGACCTGAAAT-3´; and GAPDH: 5´-ACAGTCAGCCGCATCTTCTT-3´ and 5´-ACGACCAAATCCGTTGACTC-3´. Cycle treshhold (Ct) was normalized using the known Ct from the housekeeping gene GAPDH. To compare the relative levels of gene expression of Drp1 or PSA, ddCt values were calculated using gene expression from the untreated control cells and ddCt values were expressed as the real-fold increase in gene expression.
ChIP-seq SOLEXA Library Preparation
Single-end SOLEXA sequencing libraries were prepared as previously described (28) .
Sequence Read Analysis
As previously described (28) , sequence reads were generated by the Illumina analysis pipeline version 1.3.4 and 1.4.0, and the ChIP-seq data (28) deposited in the GEO (both processed data files and raw data) at the following URLs: http://www.ncbi.nlm.nih.gov/gds?term=GSE28126
(processed data files) and http://www.ncbi.nlm.nih.gov/sra?term=SRA012454.1 (raw data files).
Illumina BeadArrays and Analysis
Illumina beadarrays were performed using standard Illumina protocols as described previously (28) . Autocorrelation analysis of Illumina gene expression data was performed as in (28 
Mitochondrial Morphology
Stably transfected mito-green LNCaP cells were maintained in androgen-depleted medium for 48h before R1881 treatment for 24h and/or CGP (50μM) for the last 1h. Cells were washed and suspended in HBSS (GIBCO InVitrogen, Grand Island, NY) and at least 200 cells were examined for mitochondrial fragmentation under a fluorescent microscope (Zeiss Axioskop, Carl
Zeiss Imaging Inc., Thornwood, NY). Mito-green cells were also grown on cover slips and treated as above. Cells were fixed with 4% paraformaldehyde and then analyzed using LSM 510 confocal microscopy (Carl Zeiss). Using the Z-stack option, signals from different planes were obtained and combined to give a single picture (maximum intensity projection). We 
Cell Proliferation Assays
Proliferation of LNCaP cells was measured using the Quick Cell Proliferation Assay Kit (BioVision, Mountain View, CA). LNCaP cells (5x10 3 per well) seeded in 96-well microtiter plate were treated with bicalutamide (50μM) and/or R1881 (1nM). CGP (50μM) was added during the last 4h of treatment. Reagent from the kit was added and samples read in a microplate reader.
For S-phase analysis, cells were treated with 1nM R1881 and fixed overnight in 70% ethanol, stained with propidium iodide (20μg/ml) and cells in S-phase were measured using a flow cytometry.
Measurement of Apoptosis
Total cell lysates (5μg) were analyzed for apoptosis using an M30 Apoptosense kit (Peviva, DiaPharma Group, West Chester, OH) as described previously (27) .
Human Prostate Tissue
Deidentified coded tissue were obtained post-surgery from prostate cancer (n=7) and hormone refractory metastatic prostate cancer patients (n=6) from the University of Michigan SPORE tissue bank. Tissues were lysed in buffer containing 7M urea, 2M thiourea, 100mM
DTT, 2% octyl glucoside and EDTA-free protease inhibitor cocktail (Roche) and the proteins were separated by SDS-PAGE, transferred to membranes and immunoblotted for Drp1, PSA (positive control) or GAPDH (loading control). 
Statistical Analyses
Results
Expression of Drp1 is Correlated with the Expression and Function of Androgen
Receptor in the Prostate
Prostate cells undergo proliferation in response to androgens. Fragmentation or fission of mitochondria is a required step in the process of mitosis and requires the involvement of Drp1, a key regulator of mitochondrial fission. Analysis of prostate cells showed that the expression of Drp1 was highest in androgen-responsive CWR-R1 cells, followed by LNCaP and LNCaPderived C4-2 cells (Fig. 1A) . The lowest levels of Drp1 were found in androgen-independent PC3 and DU145 cells. To assess the mitochondrial content of these cell lines, we also examined the COXIV expression levels (Fig. 1A) , which did not differ much in the cell lines.
Densitometric analysis of the signals showed a correlation between the expression of Drp1 and of AR (correlation coefficient of 0.927) with a P value of 0.008 (Fig. 1B) , suggesting a positive relationship between the expression of these two proteins. Furthermore, the expression of Drp1 mRNA was higher in cells expressing AR compared to AR-null cells (Fig. 1C) . Analysis of tissue samples obtained post-surgery from prostate cancer patients showed higher Drp1 levels in tissues where AR is functional, as indicated by the presence of PSA (Fig. 1D) . On the other hand, androgen-refractory metastatic tissue showed extremely low levels of Drp1 (Fig. 1D ).
These results demonstrate a positive correlation between the expression and levels of Drp1 and the expression/function of AR. dose-dependent manner (Fig. 2C ). Drp1 mRNA was also upregulated with increasing duration of R1881 treatment (Fig. 2D ).
The specificity of the Drp1 response to androgens was confirmed using the anti-androgen, bicalutamide. Bicalutamide inhibited androgen-induced Drp1 upregulation in a dose-dependent manner with a significant decrease at 50µM and a complete abrogation of androgen-induced Drp1 protein expression upon treatment with 80µM bicalutamide (Fig. 3A) . Similar analysis of Drp1 mRNA showed decreased expression with increasing concentrations of bicalutamide ( We also performed Drp1 expression array plots treating LNCaP cells with R1881 at different time points (Fig. 4B) . Each plot represents a distinct BeadArray probe for the gene. Drp1 expression was clearly increased as a result of R1881 treatment in a time-dependent manner. Based on the ChIP-seq analysis and expression beadarray time course, we have confirmed that Drp1 is androgen-regulated via an internal ARE located within a 5' untranslated region of Drp1.
Regulation of Drp1 in Androgen-Sensitive and Androgen-Refractory cells
Treatment of another androgen-sensitive prostate cancer cell line, VCaP (30) with R1881 resulted in increased Drp1 expression, which was reduced in the presence of the anti-androgen bicalutamide (Fig. 5A ), confirming our results obtained using LNCaP cells. Transition from androgen-dependent to ADI status is a critical problem in prostate cancer therapy. To determine the androgen regulation of Drp1 in ADI cells, C4-2 cells, which are known to have lost their dependence on androgen for proliferation (31, 32) , were treated with R1881, which upregulated Drp1 protein ( (Fig. 5C,D) .
Androgens Facilitated Mitochondrial Fission Induced by CGP
As Drp1 plays a critical role in mitochondrial fission, we hypothesized that its up-regulation by androgens would affect mitochondrial morphology. To verify this hypothesis, LNCaP cells, stably transfected with a construct expressing GFP protein in the mitochondria, were treated with R1881 and mitochondrial fission was scored. Contrary to our expectation, mitochondria in androgen-treated cells remained filamentous as in controls (Fig. 6A) , suggesting that the androgen-induced increase in Drp1 was not sufficient to induce significant mitochondrial fission.
To confirm the occurrence of mitochondrial fission in these cells, cells were treated with 
CGP37157 (CGP), an inhibitor of mitochondrial Ca
2+ efflux, which induced mitochondrial fission in DU145, another prostate cancer cell line (9) . As expected, CGP induced mitochondrial fission resulting in fragmented mitochondria, visualized as punctate structures (Fig. 6A) . Surprisingly, CGP in the presence of R1881 resulted in higher number of cells with fragmented mitochondria when compared to CGP treatment alone. These observations were confirmed by quantitative analysis of fragmented mitochondria (Fig. 6B) . Therefore, we suggest that androgen-induced upregulation of Drp1 is not sufficient to induce mitochondrial fragmentation, but increased levels of Drp1 readily potentiated mitochondrial fission when an appropriate mitochondrial stimulus is provided.
Androgen Affects the phosphorylation of Drp1 at Ser-616
As androgens are known to induce proliferation of prostate cells, the role of Drp1 in cell survival was investigated. As expected R1881 treatment significantly increased the proliferation of LNCaP cells compared to vehicle-treated controls (Fig. 7A, left panel) . The specificity of the response was confirmed by the ability of bicalutamide to reduce proliferation. Cell proliferation/viability was lower in CGP-treated cells even when the cells were treated also with R1881 ( Fig. 7A, left panel) . The effect of R1881 on proliferation was confirmed by flow cytometry, which showed an increased proportion of cells in S-phase (Fig. 7A, right panel) . We then investigated whether androgen treatment had any effect on phosphorylation of Drp1 at Ser-616. During mitosis, Drp1 Ser-616 is known to be phosphorylated by Cdk1/cyclin B, a protein that is known to be androgen-responsive (16, 21, 33) . Western blots revealed an increase in the phosphorylation of Drp1 at Ser-616 in R1881-treated cells compared to controls (Fig. 7B) . Since Drp1 levels increase in response to R1881, we normalized the phospho-Ser-616 Drp1 signal to total Drp1 levels to make sure that the increase in Ser-616 phosphorylation does not merely reflect increased levels of Drp1. The densitometry analysis of the above western blot clearly 
showed an increase in phosphorylation of Drp1 upon treatment of cells with R1881, establishing that androgen increases Drp1 phosphorylation at Ser-616.
Androgens Enhanced CGP-Induced Apoptosis: Mediation by Drp1
As the known function of Drp1 is in mitochondrial fission concomitant with mitosis or cell death (23, 25) , apoptosis was measured under our experimental conditions. CGP treatment for 18h resulted in a 3-fold increase in apoptosis as compared to controls (Fig. 7C) . The apoptotic response to CGP was further enhanced (to 11-fold) in the presence of R1881. There was no significant apoptosis observed in the first 4h of CGP treatment, although mitochondrial fission was observed within 1h of CGP treatment, suggesting that mitochondrial fission is an early event compared to apoptosis (Fig. 7C) . Transfection of dominant-negative Drp1 (DN-Drp1; K38A) plasmid reduced the apoptotic response in cells treated with both CGP and R1881 (Fig.   7D ), indicating that the induction of apoptosis by combination therapy required Drp1 and further confirming that androgen facilitated CGP-induced apoptosis. However, we observed no increase in apoptosis when LNCaP cells overexpressed a wild-type Drp1 (WT-Drp1) plasmid under our treatment conditions (data not shown). This result suggested that the androgeninduced increase in Drp1 is necessary but not sufficient to enhance CGP-induced apoptosis.
There may be other factors involved in the CGP-induced apoptotic response in the presence of androgen. Next, we examined the protein expression of Mfn1 and Mfn2, proteins that facilitate mitochondrial fusion, an opposing function relative to Drp1. Western blots showed that Mfn1 expression was not affected by androgen alone. However, CGP treatment in the absence or presence of androgen significantly reduced the levels of Mfn1 (Fig. 7E) . Similar analysis of Mfn2 did not show changes in expression with any treatment. These observations suggest that increased expression of Drp1, and perhaps a concomitant decrease in Mfn1, exaggerated CGPinduced mitochondrial fission and apoptosis. 
Discussion
Androgen depletion therapy is the mainstay of prostate cancer treatment. However, development of androgen-independent tumors is a major concern in patient care. Therefore, a more effective therapy would be an alternative to androgen ablation that still exhibits efficacy in inducing death of prostate cancer cells. In this manuscript we describe a mechanism to induce apoptosis in prostate cancer cells in the presence of androgens; indeed androgens facilitated the death of these cells. 
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